Abatacept fördröjer ledgångsreumatism i flera år efter avslutad behandling

1 juni 2026

Rapporterad av AI

En ettårig behandlingskur med läkemedlet abatacept kan fördröja debuten av ledgångsreumatism med upp till fyra år hos högriskpersoner. Fördelarna kvarstod långt efter att behandlingen avslutats, enligt ny forskning från King's College London.

Studien, som publicerats i The Lancet Rheumatology, följde deltagare från en tidigare klinisk prövning under fyra till åtta år. Forskarna följde 213 personer från Storbritannien och Nederländerna som löpte hög risk att utveckla ledgångsreumatism. De som fick abatacept utvecklade sjukdomen betydligt senare än de som fick placebo, där vissa fördröjningar sträckte sig flera år bortom själva behandlingsperioden.

Relaterade artiklar

A doctor giving an injection to a patient in a clinic with brain scans in the background, illustrating a trial on immune drug for depression.

Small JAMA Psychiatry trial suggests immune-targeting drug may help some treatment-resistant depression symptoms

28 maj 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.

Animal studies show experimental injection reverses osteoarthritis

Researchers at the University of Colorado Boulder have demonstrated that a single injected drug-delivery system can reverse osteoarthritis in animals within weeks. The team, led by chemical and biological engineer Stephanie Bryant, reported success in early animal experiments. They aim to advance to human trials after further safety testing.

How UC Boulder's Osteoarthritis Reversal Injection Could Transform Patient Lives

1 maj 2026 Rapporterad av AI

Promising animal studies from University of Colorado Boulder offer hope for osteoarthritis patients through a single injection that repairs damaged joints in weeks. Affecting one in six people over 30—with no cure—the disease limits daily activities, but this therapy targets root causes beyond pain management or surgery.

Hälsa

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

Hälsa

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Hälsa

CAR-T cell therapy shows early promise for HIV control

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Researchers at Aarhus University report that the hormone GLP-1—mimicked by drugs such as Wegovy—can be measured in the joint fluid of patients with inflammatory arthritis, but only at very low levels. The findings, published in The Lancet Rheumatology, suggest GLP-1–based medicines might eventually be studied for potential direct effects on joint inflammation, though the researchers say clinical trials are needed to show whether such treatment works.

New HIV pill simplifies treatment for complex cases

1 juni 2026 Rapporterad av AI

A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.

5 juni 2026 07:15

Abatacept fördröjer ledgångsreumatism i flera år efter avslutad behandling

Relaterade artiklar

Small JAMA Psychiatry trial suggests immune-targeting drug may help some treatment-resistant depression symptoms

Animal studies show experimental injection reverses osteoarthritis

How UC Boulder's Osteoarthritis Reversal Injection Could Transform Patient Lives

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

CAR-T cell therapy shows early promise for HIV control

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

New HIV pill simplifies treatment for complex cases

Large umbrella review links collagen supplements to skin and osteoarthritis benefits, not sports performance

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Caribou Biosciences presents car-t updates at healthcare conference

Intellia reports strong phase iii results for hae treatment

Hitting urate targets with gout-lowering therapy is linked to lower cardiovascular risk in large UK study

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

Shingles vaccine cuts heart risks nearly in half in study

Engineered antibody shrinks tumors body-wide in early cancer trial

Denna webbplats använder cookies